Characterization of the EP receptor subtype that mediates the inhibitory effects of prostaglandin E2 on IgE-dependent secretion from human lung mast cells
Article first published online: 21 JUN 2013
© 2013 John Wiley & Sons Ltd
Clinical & Experimental Allergy
Volume 43, Issue 7, pages 741–751, July 2013
How to Cite
Clinical & Experimental Allergy, 2013; (43) 741–751., , , , , , .
- Issue published online: 21 JUN 2013
- Article first published online: 21 JUN 2013
- Accepted manuscript online: 4 MAY 2013 11:38AM EST
- Manuscript Accepted: 18 APR 2013
- Manuscript Revised: 16 APR 2013
- Manuscript Received: 28 FEB 2013
- Pfizer Global Research & Development
Table S1. Structures and pharmacological profiles of key EP2 and EP4 receptor antagonists utilised in these studies.
Figure S1. Effect of the EP2 receptor antagonist, PF-04852946, on (a) PGE2 and (b) misoprostol. Mast cells were incubated (50 min) without or with PF-04852946 (30 nm) and then without or with PGE2 or misoprostol for 10 min before challenge with anti-IgE (2 µg/mL) for 25 min. Values are expressed as the % inhibition of control histamine release which were 23 ± 4 and 25 ± 5% for (a) and 22 ± 3 and 23 ± 3% for (b). Values are means ± SEM for 5 and 4 experiments for (a) and (b), respectively.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.